Intermountain, Cerner join bidders for $11B DoD contract

Intermountain Healthcare and Cerner have announced their intention to pursue the lucrative $11 billion Department of Defense EHR modernization contract.

This is the first bid to date that involves a major healthcare provider.

Under its agreement, Cerner and Intermountain would provide clinical governance of solutions and workflow to the defense agency’s Healthcare Management System Modernization (DHMSM) initiative.

Cerner is a member of the Leidos Partnership for Defense Health, an alliance that includes Leidos, domain experts in military health, and Accenture, a global IT and management consulting company. “If awarded, the Leidos Partnership will transition the DoD to an open, modern, secure and interoperable system, informed by the most comprehensive medical information across the continuum of care,” according to a release.

In its role, Intermountain will work with Cerner to meet the military’s specific requirements to modernize its EHR process.

“Intermountain is excited about bringing Cerner’s standards-based service strategy to the military health system,” said Stan Huff, MD, Intermountain’s CMIO, in a statement. “This strategy holds the potential for sharing of platform-independent applications and clinical decision support.”

As part of the agreement, Intermountain will serve on Cerner’s advisory and governance structures, informing Cerner’s participation in the DHMSM project from deployment to clinical systems architecture.

Intermountain currently is implementing Cerner EHR solutions and revenue cycle across its system.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.